lung cancer
Conditions
Interventions
Kanglaite Group: Receive Kanglaite injection and (or) soft capsules and combined with comprehensive treatment based on radiotherapy:None
Non-Kanglaite Group: Receive comprehensive treatment based on radiotherapy:None
Sponsors
The Second Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Male or female, aged = 18 years; 2. Diagnosed as lung cancer by pathology or cytology; 3. ECOG score = 2; 4. Expected survival = 3 months; 5. Own at least one measurable lesion according to criteria of RECIST version 1.1; 6. Participants voluntarily and strictly comply with the requirements of the study protocol and sign a written informed consent.
Exclusion criteria
Exclusion criteria: 1. Central nervous system disorders (such as epilepsy, brain tumours) and other psychiatric disorders; 2. Only have non-measurable lesions, such as hydrothorax, ascites, diffuse hepatic invasion, bone marrow invasion; 3. Women in pregnancy or lactation, or in child-bearing period refusing contraception; 4. Received CYP3A4 inducers within 4 weeks, or CYP3A4 substrates or potent, moderate CYP3A4 inhibitors within 1 week before the study initiation; 5. Those with factors which significantly affect the absorption of orally administered drugs, such as chronic diarrhoea and intestinal obstruction; 6. Be allergy to Kanglaite injection or soft capsules or the drugs in the treatment regimen; 7. Received other herbal injections or excipients for 2 full cycles; 8. Incomplete information.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression Free Survival, PFS;Objective response rate, ORR; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival, OS;Quality of Life;Tumor markers;Indicators of immune function;Safety;Clinical efficacy; | — |
Countries
China
Contacts
Public ContactHongbing Ma
The Second Affiliated Hospital of Xi'an Jiaotong University
Outcome results
None listed